9 research outputs found
Two-step polymer- and liposome- enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives
Polymer-directed enzyme prodrug therapy (PDEPT) and polymer enzyme liposome therapy (PELT) are two-step therapies developed to provide anticancer drugs site-selective intratumoral accumulation and release. Nanomedicines, such as polymer-drug conjugates and liposomal drugs, accumulate in the tumor site due to extravasation-dependent mechanism (enhanced permeability and retention â EPR â effect), and further need to cross the cellular membrane and release their payload in the intracellular compartment. The subsequent administration of a polymer-enzyme conjugate able to accumulate in the tumor tissue and to trigger the extracellular release of the active drug showed promising preclinical results. The development of polymer-enzyme, polymer-drug conjugates and liposomal drugs had undergone a vast advancement over the past decades. Several examples of enzyme mimics for in vivo therapy can be found in the literature. Moreover, polymer therapeutics often present an enzyme-sensitive mechanism of drug release. These nanomedicines can thus be optimal substrates for PDEPT and this review aims to provide new insights and stimuli toward the future perspectives of this promising combination
Amphiphilic poly(α)glutamate polymeric micelles for systemic administration of siRNA to tumors
\u3cp\u3eRNAi therapeutics carried a great promise to the area of personalized medicine: the ability to target âundruggableâ oncogenic pathways. Nevertheless, their efficient tumor targeting via systemic administration had not been resolved yet. Amphiphilic alkylated poly(α)glutamate amine (APA) can serve as a cationic carrier to the negatively-charged oligonucleotides. APA polymers complexed with siRNA to form round-shaped, homogenous and reproducible nano-sized polyplexes bearing ~50 nm size and slightly negative charge. In addition, APA:siRNA polyplexes were shown to be potent gene regulators in vitro. In light of these preferred physico-chemical characteristics, their performance as systemically-administered siRNA nanocarriers was investigated. Intravenously-injected APA:siRNA polyplexes accumulated selectively in tumors and did not accumulate in the lungs, heart, liver or spleen. Nevertheless, the polyplexes failed to induce specific mRNA degradation, hence neither reduction in tumor volume nor prolonged mice survival was seen.\u3c/p\u3
A comparative study of folate receptor-targeted doxorubicin delivery systems: Dosing regimens and therapeutic index
Ligand-receptor mediated targeting may affect differently the performance of supramolecular drug carriers depending on the nature of the nanocarrier. In this study, we compare the selectivity, safety and activity of doxorubicin (Dox) entrapped in liposomes versus Dox conjugated to polymeric nanocarriers in the presence or absence of a folic acid (FA)-targeting ligand to cancer cells that overexpress the folate receptor (FR). Two pullulan (Pull)based conjugates of Dox were synthesized, (FA-PEG)-Pull-(Cyst-Dox) and (NH2-PEG)-Pull-(Cyst-Dox). The other delivery systems are Dox loaded PEGylated liposomes (PLD, Doxil (R)) and the FR-targeted version (PLD-FA) obtained by ligand post-insertion into the commercial formulation. Both receptor-targeted drug delivery systems (DDS) were shown to interact in vitro specifically with cells via the folate ligand.
Treatment of FR-overexpressing human cervical carcinoma KB tumor-bearing mice with three-weekly injections resulted in slightly enhanced anticancer activity of PLD-FA compared to PLD and no activity for both pullulan-based conjugates. When the DDS were administered intravenously every other day, the folated-Pull conjugate and the non-folated-Pull conjugate displayed similar and low antitumor activity as free Dox. At this dosing regimen, the liposome-based formulations displayed enhanced antitumor activity with an advantage to the non-folated liposome. However, both liposomal formulations suffered from toxicity that was reversible following treatment discontinuation. Using a daily dosing schedule, with higher cumulative dose, the folated-Pull conjugate strongly inhibited tumor growth while free Dox was toxic at this regimen. For polymeric constructs, increasing dose intensity and cumulative dose strongly affects the therapeutic index and reveals a major therapeutic advantage for the FR-targeted formulation. All DDS were able to abrogate doxorubicin-induced cardiotoxicity. This study constitutes the first side-by-side comparison of two receptor-targeted ligand-bearing systems, polymer therapeutics versus nanoparticulate systems, evaluated in the same mouse tumor model at several dosing regimens
Identification of Dormancy-Associated MicroRNAs for the Design of Osteosarcoma-Targeted Dendritic Polyglycerol Nanopolyplexes
The
presence of dormant, microscopic cancerous lesions poses a
major obstacle for the treatment of metastatic and recurrent cancers.
While it is well-established that microRNAs play a major role in tumorigenesis,
their involvement in tumor dormancy has yet to be fully elucidated.
We established and comprehensively characterized pairs of dormant
and fast-growing human osteosarcoma models. Using these pairs of mouse
tumor models, we identified three novel regulators of osteosarcoma
dormancy: miR-34a, miR-93, and miR-200c. This report shows that loss
of these microRNAs occurs during the switch from dormant avascular
into fast-growing angiogenic phenotype. We validated their downregulation
in patientsâ tumor samples compared to normal bone, making
them attractive candidates for osteosarcoma therapy. Successful delivery
of miRNAs is a challenge; hence, we synthesized an aminated polyglycerol
dendritic nanocarrier, dPG-NH<sub>2</sub>, and designed dPG-NH<sub>2</sub>-microRNA polyplexes to target cancer. Reconstitution of these
microRNAs using dPG-NH<sub>2</sub> polyplexes into Saos-2 and MG-63
cells, which generate fast-growing osteosarcomas, reduced the levels
of their target genes, MET proto-oncogene, hypoxia-inducible factor
1α, and moesin, critical to cancer angiogenesis and cancer cellsâ
migration. We further demonstrate that these microRNAs attenuate the
angiogenic capabilities of fast-growing osteosarcomas <i>in vitro</i> and <i>in vivo</i>. Treatment with each of these microRNAs
using dPG-NH<sub>2</sub> significantly prolonged the dormancy period
of fast-growing osteosarcomas <i>in vivo</i>. Taken together,
these findings suggest that nanocarrier-mediated delivery of microRNAs
involved in osteosarcoma tumorâhost interactions can induce
a dormant-like state